Capital Investment Advisory Services LLC Has $2.99 Million Position in Diplomat Pharmacy Inc (DPLO)

Capital Investment Advisory Services LLC increased its stake in Diplomat Pharmacy Inc (NYSE:DPLO) by 6.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 153,842 shares of the company’s stock after purchasing an additional 9,660 shares during the quarter. Diplomat Pharmacy accounts for 1.4% of Capital Investment Advisory Services LLC’s portfolio, making the stock its 14th largest position. Capital Investment Advisory Services LLC’s holdings in Diplomat Pharmacy were worth $2,986,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Swiss National Bank boosted its holdings in Diplomat Pharmacy by 8.2% in the second quarter. Swiss National Bank now owns 90,200 shares of the company’s stock worth $2,306,000 after purchasing an additional 6,800 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Diplomat Pharmacy by 147.5% in the second quarter. SG Americas Securities LLC now owns 12,820 shares of the company’s stock worth $328,000 after purchasing an additional 7,640 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its holdings in Diplomat Pharmacy by 6.7% in the second quarter. Metropolitan Life Insurance Co. NY now owns 43,782 shares of the company’s stock worth $1,119,000 after purchasing an additional 2,746 shares during the last quarter. Brown Advisory Inc. purchased a new stake in Diplomat Pharmacy in the first quarter worth approximately $466,000. Finally, Mainstay Capital Management LLC ADV boosted its holdings in Diplomat Pharmacy by 982.9% in the second quarter. Mainstay Capital Management LLC ADV now owns 71,635 shares of the company’s stock worth $2,741,000 after purchasing an additional 65,020 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Shares of Diplomat Pharmacy stock opened at $19.78 on Wednesday. The firm has a market cap of $1.51 billion, a PE ratio of 23.55 and a beta of 1.12. Diplomat Pharmacy Inc has a 1-year low of $14.50 and a 1-year high of $28.74. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.63 and a current ratio of 0.91.



Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Monday, August 6th. The company reported $0.17 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.23 by ($0.06). The business had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.42 billion. Diplomat Pharmacy had a return on equity of 7.86% and a net margin of 0.06%. The company’s revenue was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.25 EPS. As a group, equities analysts expect that Diplomat Pharmacy Inc will post 0.83 EPS for the current fiscal year.

In related news, Director Philip R. Hagerman sold 57,500 shares of Diplomat Pharmacy stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $19.21, for a total transaction of $1,104,575.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Philip R. Hagerman sold 209,367 shares of Diplomat Pharmacy stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $19.07, for a total transaction of $3,992,628.69. The disclosure for this sale can be found here. 24.70% of the stock is currently owned by insiders.

Several research analysts have recently weighed in on the stock. ValuEngine upgraded shares of Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research note on Tuesday, October 23rd. Morgan Stanley lifted their price target on shares of Diplomat Pharmacy from $16.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 3rd. Finally, Zacks Investment Research cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Tuesday, October 23rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $26.90.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Featured Story: What is a Stop Order?

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply